Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $175
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and lowered the price target from $210 to $175.
October 10, 2023 | 3:16 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Alnylam Pharmaceuticals and lowered the price target from $210 to $175.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on Alnylam Pharmaceuticals' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100